Clinical Trial Update: Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of RO4929097, a gamma-secretase/Notch pathway inhibitor, in advanced/metastatic/recurrent triple-negative breast cancer was terminated; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-04-11